- Sutro will receive $140 million upfront and is eligible to receive up to an additional $250 million in future milestone payments in exchange for the royalty, or revenue interest, in potential future sales of Vaxcyte’s products - - Transaction provides non-dilutive growth capital to Sutro for continued pipeline advancement and further development of its cell-free protein synthesis and site-specific conjugation technologies - SOUTH SAN FRANCISCO, Calif and NEW YORK, June 26, 2023 (GLOBE NEWSWIRE